跳至主要内容
临床试验/NCT07692451
NCT07692451尚未招募2 期

A Randomized Controlled Study of Fosrolapitant and Palonosetron for the Prevention of Nausea and Vomiting Induced by Antibody-Drug Conjugates in Cancer Patients

Peking University Cancer Hospital & Institute0 个研究点目标入组 124 人开始时间: 2026年7月15日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
124
主要终点
Complete response rate

研究概览

简要总结

This study is aimed to evaluate the efficacy and safety of Fosrolapitant and Palonosetron for Antibody-drug conjugate-induced nausea and vomiting

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 18 years of age or older, of either gender
  • Has a diagnosed malignant tumor
  • has never been treated with ADCs and is to receive the first course of ADCs
  • Predicted life expectancy of ≥ 3 months
  • Has a performance status (ECOG scale) of 0 to 1
  • Adequate bone marrow, kidney, and liver function
  • Women of childbearing potential must have negative pregnancy test (serum test) results within 72 hours prior to enrollment
  • Able and willing to provide a written informed consent

结局指标

主要结局

Complete response rate

时间窗: Within 14 days after ADC administration

次要结局

未报告次要终点

研究者

发起方
Peking University Cancer Hospital & Institute
申办方类型
Other
责任方
Sponsor

相似试验